1. ZHAW digitalcollection
  2. Gesundheit
  3. Publikationen
  4. Publikationen Gesundheit
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBräutigam, Michelle-
dc.contributor.authorVolken, Thomas-
dc.contributor.authorPlattner, Alexandra-
dc.contributor.authorPassweg, Jakob R.-
dc.contributor.authorHalter, Jörg P.-
dc.contributor.authorDrexler, Beatrice-
dc.contributor.authorHeim, Dominik-
dc.contributor.authorSchaub, Stefan-
dc.contributor.authorBuser, Andreas S.-
dc.contributor.authorInfanti, Laura-
dc.contributor.authorHolbro, Andreas-
dc.date.accessioned2021-11-11T11:12:03Z-
dc.date.available2021-11-11T11:12:03Z-
dc.date.issued2021-10-29-
dc.identifier.issn1473-0502de_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/23442-
dc.description.abstractBackground and objectives: Antibodies (Ab) against HLA and HPA antigens play an important role in HCT. In this prospective study we evaluated prevalence and kinetics of HLA- and HPA-Ab after HCT, including a possible donor-recipient transfer and their clinical relevance in respect to platelet transfusion refractoriness (PTR). Materials and methods: Patients were consecutively recruited. Ab were determined by microbead assay technique and a mean fluorescence intensity cut-off of 1,000. Results: At baseline, 21 donors (42%) and 27 patients (54%) had HLA-Ab with a mean panel reactivity (cPRA) of 34.9 ± 29.4% and 46.1 ± 36.5%, respectively. We observed a significant higher number of HLA-Ab specificities in female donors and patients and a predominance of HLA-class I Ab. At day 0 we detected an increase of HLA-Ab (from 526 to 673) and cPRA (55.2 ± 31.9%). Thirty-six patients (72%) developed new HLA-Ab, mainly 3 weeks after HCT. In 7 patients an HLA-Ab with the same specificity as detected in the corresponding donor emerged, suggesting a possible transfer from the donor to the recipient. Overall, MFI showed a high variation. Type and number of transfusions were not associated with number and intensity of HLA-Ab (ρ: -0.05 – 0.02). Number of HLA-Ab, cPRA and intensity were not associated with PTR, which occurred in 9 patients (18%) and none had bleeding WHO > 2. Conclusions: Although a considerable number of patients have and develop HLA-Ab before and early after HCT, we found no association with PTR and bleeding and management should be individualized.de_CH
dc.language.isoende_CH
dc.publisherElsevierde_CH
dc.relation.ispartofTransfusion and Apheresis Sciencede_CH
dc.rightsLicence according to publishing contractde_CH
dc.subjectHLA antibodyde_CH
dc.subjectHPA antibodyde_CH
dc.subjectHematopoietic cell transplantationde_CH
dc.subjectMatched relatedde_CH
dc.subjectDonor derivedde_CH
dc.subject.ddc617: Chirurgiede_CH
dc.titleFrequency, reactivity and evolution of human leukocyte antigen and human platelet antigen antibodies in the setting of hematopoietic cell transplantationde_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementGesundheitde_CH
zhaw.organisationalunitInstitut für Public Health (IPH)de_CH
dc.identifier.doi10.1016/j.transci.2021.103301de_CH
zhaw.funding.euNode_CH
zhaw.issue2de_CH
zhaw.originated.zhawYesde_CH
zhaw.pages.start103301de_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume61de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
zhaw.author.additionalNode_CH
zhaw.display.portraitYesde_CH
Appears in collections:Publikationen Gesundheit

Files in This Item:
There are no files associated with this item.
Show simple item record
Bräutigam, M., Volken, T., Plattner, A., Passweg, J. R., Halter, J. P., Drexler, B., Heim, D., Schaub, S., Buser, A. S., Infanti, L., & Holbro, A. (2021). Frequency, reactivity and evolution of human leukocyte antigen and human platelet antigen antibodies in the setting of hematopoietic cell transplantation. Transfusion and Apheresis Science, 61(2), 103301. https://doi.org/10.1016/j.transci.2021.103301
Bräutigam, M. et al. (2021) ‘Frequency, reactivity and evolution of human leukocyte antigen and human platelet antigen antibodies in the setting of hematopoietic cell transplantation’, Transfusion and Apheresis Science, 61(2), p. 103301. Available at: https://doi.org/10.1016/j.transci.2021.103301.
M. Bräutigam et al., “Frequency, reactivity and evolution of human leukocyte antigen and human platelet antigen antibodies in the setting of hematopoietic cell transplantation,” Transfusion and Apheresis Science, vol. 61, no. 2, p. 103301, Oct. 2021, doi: 10.1016/j.transci.2021.103301.
BRÄUTIGAM, Michelle, Thomas VOLKEN, Alexandra PLATTNER, Jakob R. PASSWEG, Jörg P. HALTER, Beatrice DREXLER, Dominik HEIM, Stefan SCHAUB, Andreas S. BUSER, Laura INFANTI und Andreas HOLBRO, 2021. Frequency, reactivity and evolution of human leukocyte antigen and human platelet antigen antibodies in the setting of hematopoietic cell transplantation. Transfusion and Apheresis Science. 29 Oktober 2021. Bd. 61, Nr. 2, S. 103301. DOI 10.1016/j.transci.2021.103301
Bräutigam, Michelle, Thomas Volken, Alexandra Plattner, Jakob R. Passweg, Jörg P. Halter, Beatrice Drexler, Dominik Heim, et al. 2021. “Frequency, Reactivity and Evolution of Human Leukocyte Antigen and Human Platelet Antigen Antibodies in the Setting of Hematopoietic Cell Transplantation.” Transfusion and Apheresis Science 61 (2): 103301. https://doi.org/10.1016/j.transci.2021.103301.
Bräutigam, Michelle, et al. “Frequency, Reactivity and Evolution of Human Leukocyte Antigen and Human Platelet Antigen Antibodies in the Setting of Hematopoietic Cell Transplantation.” Transfusion and Apheresis Science, vol. 61, no. 2, Oct. 2021, p. 103301, https://doi.org/10.1016/j.transci.2021.103301.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.